

Francesco Colotta

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1725490/publications.pdf>

Version: 2024-02-01

60
papers

6,488
citations

172386

29
h-index

168321

53
g-index

60
all docs

60
docs citations

60
times ranked

9843
citing authors

#	ARTICLE	IF	CITATIONS
1	Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. <i>Carcinogenesis</i> , 2009, 30, 1073-1081.	1.3	2,335
2	The origin and function of tumor-associated macrophages. <i>Trends in Immunology</i> , 1992, 13, 265-270.	7.5	966
3	The type II α ~decoy~ receptor: A novel regulatory pathway for interleukin 1. <i>Trends in Immunology</i> , 1994, 15, 562-566.	7.5	337
4	Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: Prevention of reperfusion injury. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 11791-11796.	3.3	310
5	Modulation of inflammatory and immune responses by vitamin D. <i>Journal of Autoimmunity</i> , 2017, 85, 78-97.	3.0	250
6	Targeting the Mitotic Checkpoint for Cancer Therapy with NMS-P715, an Inhibitor of MPS1 Kinase. <i>Cancer Research</i> , 2010, 70, 10255-10264.	0.4	152
7	Synthesis and Immunosuppressive Activity of Novel Prodigiosin Derivatives. <i>Journal of Medicinal Chemistry</i> , 2000, 43, 2557-2565.	2.9	149
8	Inhibition of the chemokine receptor CXCR2 prevents kidney graft function deterioration due to ischemia/reperfusion. <i>Kidney International</i> , 2005, 67, 1753-1761.	2.6	126
9	2-Arylpropionic CXC Chemokine Receptor 1 (CXCR1) Ligands as Novel Noncompetitive CXCL8 Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 4312-4331.	2.9	115
10	Induction of apoptosis in human leukemic cells by the ether lipid 1-octadecyl-2-methyl-RAC-glycero-3-phosphocholine. A possible basis for its selective action. <i>International Journal of Cancer</i> , 1993, 53, 124-130.	2.3	112
11	Identification of α ,1,4,4-Tetramethyl-8-[[4-(4-methylpiperazin-1-yl)phenyl]amino]-4,5-dihydro-1H-pyrazolo[4,3- α]quinazoline-3-carboxamide (PHA-848125), a Potent, Orally Available Cyclin Dependent Kinase Inhibitor. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 5152-5163.	2.9	111
12	Repertaxin, a novel inhibitor of rat CXCR2 function, inhibits inflammatory responses that follow intestinal ischaemia and reperfusion injury. <i>British Journal of Pharmacology</i> , 2004, 143, 132-142.	2.7	106
13	Targeting Cell Division Cycle 7 Kinase: A New Approach for Cancer Therapy. <i>Clinical Cancer Research</i> , 2010, 16, 4503-4508.	3.2	104
14	Inhibition of interleukin-8 (CXCL8/IL-8) responses by repertaxin, a new inhibitor of the chemokine receptors CXCR1 and CXCR2. <i>Biochemical Pharmacology</i> , 2005, 69, 385-394.	2.0	99
15	IL-1 β Scavenging by the Type II IL-1 Decoy Receptor in Human Neutrophils. <i>Journal of Immunology</i> , 2003, 170, 5999-6005.	0.4	87
16	A chemoattractant expressed in human sarcoma cells (tumor-derived chemotactic factor, TDCF) is identical to monocyte chemoattractant protein-1/monocyte chemotactic and activating factor (MCP-1/MCAF). <i>International Journal of Cancer</i> , 1990, 45, 795-797.	2.3	86
17	Neuroprotection with the CXCL8 inhibitor repertaxin in transient brain ischemia. <i>Cytokine</i> , 2005, 30, 125-131.	1.4	85
18	Crucial pathophysiological role of CXCR2 in experimental ulcerative colitis in mice. <i>Journal of Leukocyte Biology</i> , 2007, 82, 1239-1246.	1.5	83

#	ARTICLE	IF	CITATIONS
19	Divergent effects of interleukin-10 on cytokine production by mononuclear phagocytes and endothelial cells. <i>European Journal of Immunology</i> , 1993, 23, 2692-2695.	1.6	73
20	Expression of interleukin-1 receptor antagonist (IL-1ra) by human circulating polymorphonuclear cells. <i>European Journal of Immunology</i> , 1993, 23, 570-573.	1.6	69
21	Macrophage infiltration and growth of sarcoma clones expressing different amounts of monocyte chemotactic protein/IE. <i>International Journal of Cancer</i> , 1991, 49, 431-435.	2.3	66
22	Intraperitoneal administration of interferon β in ovarian cancer patients. <i>Cancer</i> , 1985, 56, 294-301.	2.0	61
23	Cdc7 Kinase Inhibitors: 5-Heteroaryl-3-Carboxamido-2-Aryl Pyrroles as Potential Antitumor Agents. 1. Lead Finding. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 7296-7315.	2.9	60
24	Dual Targeting of CDK and Tropomyosin Receptor Kinase Families by the Oral Inhibitor PHA-848125, an Agent with Broad-Spectrum Antitumor Efficacy. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 2243-2254.	1.9	48
25	The induction of apoptosis is a common feature of the cytotoxic action of ether-linked glycerophospholipids in human leukemic cells. <i>International Journal of Cancer</i> , 1994, 57, 645-649.	2.3	43
26	Key role of proline-rich tyrosine kinase 2 in interleukin-8 (CXCL8/IL-8)-mediated human neutrophil chemotaxis. <i>Immunology</i> , 2004, 111, 407-415.	2.0	43
27	Recent developments in the cell biology of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor: activities on endothelial cells. <i>International Journal of Clinical and Laboratory Research</i> , 1993, 23, 8-12.	1.0	36
28	Effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) on expression of adhesion molecules and production of cytokines in blood monocytes and ovarian cancer-associated macrophages. <i>International Journal of Cancer</i> , 1995, 60, 300-307.	2.3	36
29	IL-8 induces a specific transcriptional profile in human neutrophils: synergism with LPS for IL-1 production. <i>European Journal of Immunology</i> , 2004, 34, 2286-2292.	1.6	30
30	Induction by transforming growth factor- β 1 of the interleukin-1 receptor antagonist and of its intracellular form in human polymorphonuclear cells. <i>European Journal of Immunology</i> , 1994, 24, 3194-3198.	1.6	28
31	Requirements for the Different Cysteines in the Chemotactic and Desensitizing Activity of Human Thioredoxin. <i>Antioxidants and Redox Signaling</i> , 2005, 7, 1189-1194.	2.5	25
32	Monocyte Chemotactic Protein-1 (MCP-1): Signal Transduction and Involvement in the Regulation of Macrophage Traffic in Normal and Neoplastic Tissues. <i>Advances in Experimental Medicine and Biology</i> , 1993, 351, 47-54.	0.8	24
33	Pharmacological Inhibition of Interleukin-8 (CXCL8) as a New Approach for the Prevention and Treatment of Several Human Diseases. <i>Current Medicinal Chemistry Anti-inflammatory & Anti-allergy Agents</i> , 2003, 2, 67-79.	0.4	23
34	Interleukin-2 Receptor Expression in Human Mast Cells and Basophils. <i>International Archives of Allergy and Immunology</i> , 1990, 91, 8-14.	0.9	22
35	An HGF-MSP chimera disassociates the trophic properties of scatter factors from their pro-invasive activity. <i>Nature Biotechnology</i> , 2002, 20, 488-495.	9.4	22
36	Arachidonic acid and leukotriene B ₄ induce aggregation of human peripheral blood mononuclear leucocytes in vitro. <i>British Journal of Haematology</i> , 1984, 58, 137-146.	1.2	17

#	ARTICLE	IF	CITATIONS
37	Simple, rapid and accurate molecular diagnosis of acute promyelocytic leukemia by loop mediated amplification technology. <i>Oncoscience</i> , 2014, 2, 50-58.	0.9	15
38	Interleukin-6 gene expression and production induced in human monocytes by membrane proteoglycans from <i>Klebsiella pneumoniae</i> . <i>International Journal of Immunopharmacology</i> , 1990, 12, 397-402.	1.1	14
39	Interleukin-1 and tumor necrosis factor production in acute non-lymphoid leukemia. <i>European Journal of Haematology</i> , 1989, 42, 16-23.	1.1	14
40	Placental Growth Factor-1 Potentiates Hematopoietic Progenitor Cell Mobilization Induced by Granulocyte Colony-Stimulating Factor in Mice and Nonhuman Primates. <i>Stem Cells</i> , 2007, 25, 252-261.	1.4	12
41	Therapeutic efficacy of the pan-cdk inhibitor PHA-793887 in vitro and in vivo in engraftment and high-burden leukemia models. <i>Experimental Hematology</i> , 2010, 38, 259-269.e2.	0.2	12
42	A low plasma 1,25(OH) ₂ vitamin D/PTH (1-84) ratio predicts worsening of renal function in patients with chronic heart failure. <i>International Journal of Cardiology</i> , 2016, 224, 220-225.	0.8	12
43	Chemotactic cytokine gene expression and production induced in human monocytes by membrane proteoglycans from <i>Klebsiella pneumoniae</i> . <i>International Journal of Immunopharmacology</i> , 1991, 13, 631-637.	1.1	11
44	Induction of the interleukin-1 decoy receptor by glucocorticoids. <i>Trends in Pharmacological Sciences</i> , 1994, 15, 138-139.	4.0	9
45	Acute lymphoblastic leukemia hand-mirror cells. <i>Blut</i> , 1983, 47, 297-306.	1.2	8
46	Vasodilation in multistep paradigm of leucocyte extravasation. <i>Lancet</i> , The, 1994, 343, 1499-1500.	6.3	8
47	Cancer chemotherapeutics as immunomodulators. <i>Seminars in Immunopathology</i> , 1985, 8, 361-374.	4.0	7
48	Differential expression of Raf-1 protooncogene in resting and activated human leukocyte populations. <i>Experimental Cell Research</i> , 1991, 194, 284-288.	1.2	7
49	Interleukin 1. , 1998, , 1-18.		6
50	Anticancer Drug Discovery and Development. <i>Advances in Experimental Medicine and Biology</i> , 2008, 610, 19-42.	0.8	5
51	Rapid killing of actinomycin D-treated tumor cells-cytotoxicity of cell-free monocyte supernatants. <i>Immunology Letters</i> , 1985, 11, 351-355.	1.1	3
52	Increased expression of urokinase mRNA in bovine aortic endothelial cells treated with propranolol. <i>Biochemical and Biophysical Research Communications</i> , 1989, 160, 977-981.	1.0	3
53	c-fos proto-oncogene expression in human NK/LGL cells: Expression is not constitutive and is associated with functional activation. <i>International Journal of Cancer</i> , 1988, 42, 709-711.	2.3	2
54	Dissociation between induction of ornithine decarboxylase and oxidative burst by phorbol esters in a macrophage cell line. <i>Carcinogenesis</i> , 1986, 7, 1297-1299.	1.3	1

#	ARTICLE	IF	CITATIONS
55	c-Fos protooncogene expression in human normal peripheral blood leukocytes. Cytotechnology, 1987, 1, 61-64.	0.7	0
56	Protooncogene expression in normal and tumor-infiltrating phagocytes. Immunology Letters, 1987, 16, 311-313.	1.1	0
57	Editorial [Targeting Genetic Instability in Cancer Cells (Guest Editor: Francesco Colotta)]. Current Drug Targets, 2010, 11, 1293-1295.	1.0	0
58	Biological Significance and Therapeutic Potential of Tumor-Associated Leukocytes. , 1993, , 87-94.		0
59	Cytokine Regulation of Tumor-Associated Macrophages: Therapeutic Implications. , 1993, , 249-258.		0
60	Formation of high density lipoprotein-like particles from chylomicrons. Research in Clinic and Laboratory, 1982, 12, 51-62.	0.3	0